Skip to main content
Premium Trial:

Request an Annual Quote

CyBio, Promega to Co-Develop High-Throughput Liquid-Handling Apps

NEW YORK (GenomeWeb News) — CyBio and Promega plan to co-develop and co-market new high-throughput liquid-handling applications based on CyBio’s liquid-handling instruments, the company said today.
Under the agreement, CyBio and Promega will jointly develop and market validated application protocols for high-throughput screening processes in drug development and life science research.
CyBio said its CyBi-Well pipettor and Promega’s MultiTox kits together create a “robust automation solution” that is user-friendly and easy to implement.
The collaborators also will automate Promega’s cell-based multiplex-assays, which CyBio said increases “data quality in toxicity studies” of drug compounds.
Financial terms of the agreement were not released.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.